Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis

Registry ID

EUCTR2013-005333-21

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2015-01-08

Last update

2026-08-16

Conditions

• Pulmonary sarcoidosis

Summary

To compare the effect of ACZ885 versus placebo on the clinical disease activity of sarcoidosis patients

Locations

• , , Netherlands

View on source registry